Premium
Vitiligo and lipohypertrophy surrounding insulin injection sites in a patient with type 1 diabetes
Author(s) -
Hedges Karen,
Poole Ruth
Publication year - 2016
Publication title -
practical diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.205
H-Index - 24
eISSN - 2047-2900
pISSN - 2047-2897
DOI - 10.1002/pdi.1994
Subject(s) - depigmentation , medicine , vitiligo , lipoatrophy , type 1 diabetes , diabetes mellitus , dermatology , type 2 diabetes , insulin , surgery , endocrinology , immunology , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy
We present a case of vitiligo associated with lipohypertrophy in a patient with type 1 diabetes on Lantus and Novorapid subcutaneous insulin. The patient, a 55‐year‐old woman, was diagnosed with type 1 diabetes 53 years ago. Following 11 years using Novorapid and Lantus she developed lipohypertrophy at her injection sites with associated depigmentation of the skin. The depigmentation has recurred following changing injection sites. We believe this is the first case of its kind to be reported in the literature and teaches a valuable lesson about the importance of examining injection sites. Copyright © 2016 John Wiley & Sons.